+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

All Ages
All Genders
ID07190677

Real-World Study of First-Line Nivolumab, Ipilimumab, and Chemotherapy for Metastatic Non-Small Cell Lung Cancer in Italy

Led by Fondazione IRCCS Policlinico San Matteo di Pavia · Updated on 2025-09-24

300

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are collecting real-life data on the use of nivolumab plus ipilimumab combined with chemotherapy as a first-line treatment for metastatic non-small cell lung cancer NSCLC. This study is observational and ambispective, meaning it includes both retrospective data from January 2022 and prospective data collection continuing until December 31, 2025. The main goals are to evaluate progression-free survival PFS and overall survival OS in a real-world patient population, along with secondary outcomes such as response rates, treatment duration, and treatment-related adverse events. The study gathers detailed information on patient characteristics like age, sex, smoking status, and comorbidities, as well as disease features including NSCLC type, metastatic sites, and molecular profile. Treatment timelines, such as therapy start dates, number of cycles, reasons for ending therapy, and responses to treatment, are also recorded. Adverse drug reactions are monitored using established criteria, and data collection is maintained through an electronic data capture system. After December 2025, participants will be followed for two additional years to track long-term outcomes. Participants provide informed consent and are observed during their routine treatment with nivolumab plus ipilimumab and chemotherapy. Researchers review survival outcomes from therapy initiation to disease progression or death, as well as the overall response and safety of treatment. The study aims to reflect the effectiveness and risks of this therapy in everyday clinical practice. Data collection will continue until the end of 2025 with follow-up extending for two years to monitor patient outcomes comprehensively.

CONDITIONS

Brief Title

First-line Therapy With Nivolumab Plus Ipilimumab in Combination With Chemotherapy for Metatastatic NSCLC (NICReWo Trial)

Research Team

F

Francesco Agustoni, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here